S
Sonoma Pharmaceuticals, Inc. (SNOA)
NCM – Real Time Price. Currency in USD
1.18
+0.02 (1.72%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.18
+0.02 (1.72%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.84 | 2.52 | 10 | |
| Quick ratio | 1.97 | 1.78 | 9.0 | |
| Debt to Equity | 0.19 | -0.80 | 9.0 | |
| Debt to Assets | 0.05 | 0.73 | 9.0 | |
| Interest coverage | N/A | -13.90 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 13M | 13M | 13M | 14M | 18M |
| Gross Profit | 4M | 4M | 5M | 5M | 7M |
| Operating Income | -6M | -5M | -5M | -4M | -3M |
| Net Income | -5M | -5M | -5M | -3M | -3M |
| EBITDA | -5M | -4M | -5M | -4M | -3M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 48.25 | -57.88 | 5.5 |
| Next quarter | 24.28 | 18.78 | 9.5 |
| Current year | 44.57 | 28.47 | 10 |
| Next year | 15.76 | 65.22 | 9.5 |
| Weighted average score | 8.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -22.38 | -53.36 | -172.03 | -25.73 | 1.0 |
| Y/Y | 22.03 | 11.75 | 40.86 | -244.04 | 7.0 |
| 3y average | 4.42 | 11.12 | 67.76 | 36.34 | 7.8 |
| 5y average | -3 | -3.4 | N/A | 22.32 | 3.3 |
| Weighted average score | 4.8 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $2.6M significantly exceed its total debt $655.0K, ensuring strong financial flexibility
Total current assets $12.0M exceed Total current liabilities $4.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (-0.8), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$811.0K limits the company's ability to reinvest or pay down debt